Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
I
116TH CONGRESS
1ST SESSION H. R. 2710
To amend title XVIII of the Social Security Act to improve access to innova-
tive new medical devices furnished to individuals with end stage renal
disease under part B of the Medicare program by establishing a new
device add-on payment adjustment under such part.
IN THE HOUSE OF REPRESENTATIVES
MAY 14, 2019
Mr. DANNY K. DAVIS of Illinois (for himself and Mr. HOLLINGSWORTH) intro-
duced the following bill; which was referred to the Committee on Energy
and Commerce, and in addition to the Committee on Ways and Means,
for a period to be subsequently determined by the Speaker, in each case
for consideration of such provisions as fall within the jurisdiction of the
committee concerned
A BILL
To amend title XVIII of the Social Security Act to improve
access to innovative new medical devices furnished to
individuals with end stage renal disease under part B
of the Medicare program by establishing a new device
add-on payment adjustment under such part.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
SECTION 1. SHORT TITLE.
3
This Act may be cited as the ‘‘Patient Access to
4
ESRD New Innovative Devices Act’’.
5
VerDate Sep 11 2014
06:39 May 23, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2710.IH
H2710
kjohnson on DSK79L0C42 with BILLS
2
•HR 2710 IH
SEC. 2. FINDINGS.
1
Congress finds the following:
2
(1) There are approximately 400,000 Medicare
3
beneficiaries with end-stage renal disease, making up
4
1 percent of the Medicare population but accounting
5
for approximately 7 percent of all Medicare spend-
6
ing.
7
(2) Expected remaining lifetime for dialysis pa-
8
tients under 80 years old is one-third as long as
9
their counterparts without ESRD, and for dialysis
10
patients over 80 years old, it is one-half as long as
11
that of their counterparts without ESRD.
12
(3) On average, hemodialysis patients are hos-
13
pitalized nearly twice per year and about 30 percent
14
have an unplanned rehospitalization within the 30
15
days following discharge, contributing to high costs
16
for treating ESRD Medicare beneficiaries.
17
(4) There is a lack of innovative new devices for
18
ESRD Medicare beneficiaries, in part because of the
19
lack of reimbursement incentives for novel devices.
20
SEC. 3. INCREASING PATIENT ACCESS TO INNOVATIVE DE-
21
VICES FOR THE TREATMENT OF ESRD.
22
As part of the promulgation of the annual rule for
23
the Medicare end stage renal disease prospective payment
24
system under section 1881(b)(14) of the Social Security
25
Act (42 U.S.C. 1395rr(b)(14)) for calendar year 2020, the
26
VerDate Sep 11 2014
06:39 May 23, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2710.IH
H2710
kjohnson on DSK79L0C42 with BILLS
3
•HR 2710 IH
Secretary of Health and Human Services (in this section
1
referred to as the ‘‘Secretary’’) shall establish a process
2
to provide—
3
(1) an add-on payment adjustment for a new
4
medical device reviewed by the Food and Drug Ad-
5
ministration under section 513(f)(2) or section 515
6
of the Federal Food, Drug, and Cosmetic Act (21
7
U.S.C. 360c, 360e) on or after January 1, 2020,
8
and furnished to a beneficiary for the diagnosis,
9
treatment, or management of end stage renal dis-
10
ease; and
11
(2) for such adjustment to be implemented in
12
a nonbudget neutral manner under subparagraph
13
(D)(iv) of such section 1881(b)(14).
14
Æ
VerDate Sep 11 2014
06:39 May 23, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H2710.IH
H2710
kjohnson on DSK79L0C42 with BILLS